THERAPEUTIC FOCUS
RESEARCH & DEVELOPMENT
PUBLICATION
PARTNERING
Shareholder Tools
Briefcase Printed Materials Email Alerts Download Center snapshot RSS

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

All Releases
View Summary Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
31 Mar 2014
PDF 105.8 KB Add to Briefcase
View Summary Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
27 Feb 2014
PDF 91.4 KB Add to Briefcase
View Summary Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
24 Feb 2014
PDF 15.1 KB Add to Briefcase
View Summary Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
21 Feb 2014
PDF 16.7 KB Add to Briefcase
View Summary Amarin to Present at the 2014 Leerink Global Healthcare Conference
6 Feb 2014
PDF 17.2 KB Add to Briefcase
View Summary Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
4 Feb 2014
PDF 64.3 KB Add to Briefcase
View Summary Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request
21 Jan 2014
PDF 69.3 KB Add to Briefcase
View Summary Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed
15 Jan 2014
PDF 66.1 KB Add to Briefcase
View Summary Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed
20 Dec 2013
PDF 66.0 KB Add to Briefcase
View Summary Amarin Announces Leadership Changes
16 Dec 2013
PDF 19.3 KB Add to Briefcase
View Summary Amarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations
2 Dec 2013
PDF 19.0 KB Add to Briefcase
View Summary Amarin Reports Third Quarter 2013 Financial Results and Provides Update on Operations
7 Nov 2013
PDF 115.0 KB Add to Briefcase
View Summary Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
31 Oct 2013
PDF 15.1 KB Add to Briefcase
View Summary Amarin Announces Plans to Reduce Expenses by Decreasing Staff Following Recent FDA Advisory Committee Vote
22 Oct 2013
PDF 17.1 KB Add to Briefcase
View Summary Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia
16 Oct 2013
PDF 60.7 KB Add to Briefcase
View Summary Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR Indication
16 Oct 2013
PDF 14.3 KB Add to Briefcase
View Summary Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa(R)
9 Oct 2013
PDF 97.5 KB Add to Briefcase
View Summary Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled
3 Oct 2013
PDF 18.0 KB Add to Briefcase
View Summary Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients
25 Sep 2013
PDF 64.9 KB Add to Briefcase
View Summary Amarin to Present at the 2013 Aegis Capital Healthcare Conference
18 Sep 2013
PDF 15.1 KB Add to Briefcase
Showing 1-20 of 191 Page: 1 2 3 4 5 ... 10  Next 20
Add to Briefcase = add release to Briefcase